[{"id":"80dc0fa0-4b17-4809-8319-1176fedb9aae","acronym":"MUCIGLIO-01","url":"https://clinicaltrials.gov/study/NCT06001281","created_at":"2023-08-21T14:08:41.370Z","updated_at":"2024-07-02T16:35:21.182Z","phase":"","brief_title":"Predictive Value of Soluble CD146 in Glioblastoma Patients","source_id_and_acronym":"NCT06001281 - MUCIGLIO-01","lead_sponsor":"Assistance Publique Hopitaux De Marseille","biomarkers":" MCAM","pipe":" | ","alterations":" IDH wild-type","tags":["MCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 01/30/2024","start_date":" 01/30/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-02"},{"id":"4ac896c7-cc69-4fa2-8df9-7957251b05cf","acronym":"PIONeeR","url":"https://clinicaltrials.gov/study/NCT03493581","created_at":"2021-01-18T17:12:14.627Z","updated_at":"2024-07-02T16:35:44.685Z","phase":"","brief_title":"Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)","source_id_and_acronym":"NCT03493581 - PIONeeR","lead_sponsor":"Assistance Publique Hopitaux De Marseille","biomarkers":" EGFR • PD-L1 • ALK • ROS1 • MCAM","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • PD-L1 • ALK • ROS1 • MCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 03/08/2018","start_date":" 03/08/2018","primary_txt":" Primary completion: 03/08/2024","primary_completion_date":" 03/08/2024","study_txt":" Completion: 08/12/2024","study_completion_date":" 08/12/2024","last_update_posted":"2023-06-26"},{"id":"9e38132f-f6aa-4337-816d-1a1db58ab598","acronym":"","url":"https://clinicaltrials.gov/study/NCT00835978","created_at":"2021-01-18T03:10:54.824Z","updated_at":"2024-07-02T16:37:21.625Z","phase":"Phase 2","brief_title":"Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer","source_id_and_acronym":"NCT00835978","lead_sponsor":"Pfizer","biomarkers":" FLT4 • MCAM • CD31 • ENG • PECAM1","pipe":"","alterations":" ","tags":["FLT4 • MCAM • CD31 • ENG • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2017-05-30"}]